Detalles de la búsqueda
1.
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.
Future Oncol;
2024 Jan 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38214149
2.
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
Oncologist;
27(4): 255-265, 2022 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35274704
3.
An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
BMC Cancer;
21(1): 802, 2021 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34253172
4.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.
Future Oncol;
16(34): 2799-2808, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-32854536
5.
What could the future hold for treatment sequencing in cancer medicine? An interview with Angela Märten.
Future Oncol;
15(25): 2891-2893, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31424270
6.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.
Future Oncol;
15(25): 2905-2914, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31370698
7.
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.
Future Oncol;
14(27): 2861-2874, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30336693
8.
Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
Oncologist;
20(10): 1167-74, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26354527
9.
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Acta Oncol;
54(7): 993-1000, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25924969
10.
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Oncologist;
19(10): 1100-9, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-25232040
11.
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104.
BMC Cancer;
14: 624, 2014 Aug 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-25164437
12.
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Gut;
62(5): 751-9, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22773551
13.
Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.
Onco Targets Ther;
17: 267-280, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38567193
14.
Technical considerations for isolated limb perfusion: A consensus paper.
Eur J Surg Oncol;
50(6): 108050, 2024 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38498966
15.
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report.
Front Oncol;
12: 834704, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35574304
16.
Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies.
Onco Targets Ther;
15: 873-882, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36033903
17.
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).
Lung Cancer;
162: 9-15, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34649106
18.
Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked.
Cancer Immunol Immunother;
59(6): 829-39, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20024547
19.
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Anticancer Drugs;
21(1): 94-100, 2010 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-19770635
20.
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.
Adv Ther;
37(2): 759-769, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31863283